Development of Leuven’s candidate medicine against nerve disease ALS moves into higher gear

The European Medicines Agency (EMEA) has recognized a Leuven lab’s candidate medicine to combat the neurodegenerative disease ALS (Amyotrophic Lateral Sclerosis) as a 'weesgeneesmiddel' (‘orphan medicine’). This name is given to promising medicines that would not reach the market without extra financial and administrative stimulus.
Read more

NeuroNova´s drug candidate sNN0029 for ALS/Lou Gehrig´s disease receives orphan designation by the European Medicines Agency

NeuroNova, a privately held Swedish biopharmaceutical company pioneering treatments for disorders of the central nervous system, has received orphan designation by the European Medicines Agency for its clinical candidate sNN0029 for patients with Amyotrophic Lateral Sclerosis (ALS), also referred to as Lou Gehrig´s Disease. This program is presently in clinical development phase I/II.
Read more

Research on heart and vascular diseases earns Peter Carmeliet of VIB and K.U.Leuven the Ernst Jung Medical Award 2010

His pioneering research on heart and vascular diseases and thrombosis has earned Peter Carmeliet of the Vlaams Instituut voor Biotechnologie (VIB) and the Katholieke Universiteit Leuven (K.U.Leuven) the prestigious Ernst Jung Medical Award, one of the highest European prizes for biomedical research.
Read more

 Top scientist leaves US for Flanders

Dietmar Schmucker (Ph.D.), neuroscientist of international fame, leaves the world­
renowned  Harvard  University  to  start  a  new  lab  at  VIB  (the  Flanders  Institute  for 
Biotechnology) and K.U.Leuven. Dietmar brings an international group of researchers from his 
Boston lab with him.  The transition of Dietmar Schmucker confirms a trend: top scientists are 
attracted by the outstanding research opportunities offered in Flanders. The internationally 
recognized scientific excellence in molecular biology paired with an attractive quality of life, 
attracted the highly motivated neuroscientist to Flanders. 
Read more

First trial in patients with a potential treatment of the incurable ALS muscle disease

Permission has been granted to start the first safety and tolerability trial on patients for a remedy for ALS.
Read more